NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Dr. Reddy's Q3FY26: Revenue Grows 4.4% to ₹8,727 Cr; Adjusted EBITDA Margin at 24.8%
Dr. Reddy's reported a resilient Q3FY26 with revenue growth of 4.4% YoY to ₹8,727 crores, driven by double-digit growth in the base business excluding Lenalidomide. Reported PAT declined 14% YoY to ₹1,210 crores, impacted by lower Lenalidomide sales and a one-time provision for new Indian Labour Codes. Adjusted for this one-off, the EBITDA margin remained healthy at 24.8%. The company continues to strengthen its pipeline with the US BLA filing for Abatacept and DCGI approval for Semaglutide in India.
முக்கிய அம்சங்கள்
Consolidated revenue reached ₹8,727 crores, up 4.4% YoY, supported by branded markets and favorable forex.Adjusted EBITDA margin stood at 24.8% after excluding a one-time labor code provision; reported margin was 23.5%.Net cash surplus remains robust at ₹3,069 crores ($342 million) as of December 31, 2025.Received DCGI marketing authorization for Semaglutide injection in India and filed US BLA for Abatacept biosimilar.USFDA issued a Complete Response Letter (CRL) for Denosumab biosimilar due to partner Alvotech's facility observations.
👀 கவனிக்க வேண்டியவை
Investors should monitor the ramp-up of the base business to offset the declining Lenalidomide contribution and track regulatory progress on the Semaglutide and Abatacept pipelines. The stock remains a solid play on biosimilars and emerging market growth, supported by a strong net-cash balance sheet.
Dr. Reddy's Q3 FY26: Revenue up 4.4% to ₹8,727 Cr; India and Europe Segments Show Robust Growth
Dr. Reddy's reported a steady Q3 FY26 with revenues of ₹8,727 crore, supported by double-digit growth in India (+19%) and Europe (+20%). However, North America revenues declined 12% YoY to ₹2,964 crore due to lower Lenalidomide sales and pricing pressure. The company maintained a healthy net cash surplus of ₹3,069 crore and an annualized RoCE of 20.4%. Key strategic progress includes the launch of the Hepatitis-E vaccine and securing marketing authorization for Semaglutide in India.
முக்கிய அம்சங்கள்
Consolidated revenue grew 4.4% YoY to ₹8,727 Cr, while EBITDA margin stood at 23.5%.India business outperformed the market with 19% YoY growth, reaching ₹1,603 Cr.North America sales fell 12% YoY to ₹2,964 Cr, impacted by high-base effects of Lenalidomide.Europe revenue surged 20% YoY to ₹1,448 Cr, driven by the integration of the NRT business.Maintained a strong balance sheet with a net cash surplus of ₹3,069 Cr as of Dec 31, 2025.
👀 கவனிக்க வேண்டியவை
Investors should monitor the recovery in the US portfolio and the ramp-up of the biosimilar pipeline. The stock remains a solid long-term play given its strong cash position and diversification into high-growth areas like vaccines and GLP-1s.
Dr. Reddy's Q3FY26 Revenue Up 4.4% YoY to ₹87,268 Mn; Net Profit Drops 15.3% YoY
Dr. Reddy's Laboratories reported a 4.4% YoY increase in consolidated revenue for Q3FY26, reaching ₹87,268 million, though revenue saw a slight 0.9% sequential decline. Profitability was significantly impacted as Net Profit fell 15.3% YoY to ₹11,896 million, driven by gross margin compression from 58.7% to 53.6%. The results were further weighed down by a one-time incremental cost of ₹1,170 million due to the implementation of New Labour Codes in India and a ₹695 million tax provision for a foreign subsidiary. While the Global Generics segment remains a growth driver, the Pharmaceutical Services and Active Ingredients (PSAI) segment saw a decline in revenue.
முக்கிய அம்சங்கள்
Consolidated Revenue for Q3FY26 stood at ₹87,268 million, up 4.4% YoY but down 0.9% QoQ.Gross Margin contracted to 53.6% in Q3FY26 compared to 58.7% in Q3FY25 and 54.7% in Q2FY26.Net Profit attributable to equity holders declined to ₹12,098 million from ₹14,133 million in the year-ago period.Recognized a one-time employee benefit cost of ₹1,170 million following the enactment of New Labour Codes.Global Generics revenue grew to ₹79,113 million, while PSAI segment revenue fell to ₹9,675 million from ₹10,221 million YoY.
👀 கவனிக்க வேண்டியவை
Investors should be cautious due to the sharp contraction in gross margins and the impact of one-time regulatory costs on the bottom line. Monitor the management's commentary on margin recovery and the performance of the PSAI segment in upcoming quarters.
Dr. Reddy's Launches First Generic Extra-Strength Pataday in U.S. (Market Size $69.9M)
Dr. Reddy's Laboratories has announced the first-to-market launch of Olopatadine Hydrochloride Ophthalmic Solution 0.7% (OTC) in the U.S. market. This product is the generic equivalent of Extra-Strength Pataday Once Daily Relief, which recorded U.S. sales of approximately $69.9 million for the 52-week period ending December 27, 2025. The launch strengthens the company's existing OTC eye-care portfolio, which already includes 0.1% and 0.2% strengths. Being first-to-market allows Dr. Reddy's to capture a significant share of the branded market early.
முக்கிய அம்சங்கள்
First-to-market generic launch of Extra-Strength Pataday (0.7% strength) in the U.S. OTC marketTargeting a market segment with annual sales of approximately $69.9 millionExpands existing eye-care portfolio which already includes 0.1% and 0.2% strengthsUSFDA approved antihistamine eye drop for temporary relief of itchy eyesProduct available in a 2.5 mL bottle format for retail customers
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive development that reinforces Dr. Reddy's strong execution in the U.S. OTC segment. Monitor the company's ability to maintain market share as other generic competitors eventually enter the space.
Dr. Reddy's Receives USFDA Post-Application Action Letter for Bachupally Biologics Facility
Dr. Reddy's Laboratories has received a Post-Application Action Letter (PAAL) from the USFDA regarding its biologics manufacturing facility in Bachupally, Hyderabad. This letter follows the regulator's review of the company's responses to a Pre-Approval Inspection (PAI) conducted in September 2025. The PAAL indicates that the USFDA has further queries that must be addressed before the application can proceed. The company has stated it will work closely with the USFDA to resolve these issues, though no specific timeline for resolution was provided.
முக்கிய அம்சங்கள்
Received Post-Application Action Letter (PAAL) from USFDA on January 10, 2026Relates to the biologics manufacturing facility located in Bachupally, HyderabadFollows a Pre-Approval Inspection (PAI) originally conducted in September 2025Company committed to addressing specific queries raised by the USFDA to secure approval
👀 கவனிக்க வேண்டியவை
Investors should monitor the progress of these regulatory queries as biologics are a key growth driver; any significant delay in facility approval could impact the launch timeline of new products.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Dr. Reddy's Receives USFDA CRL for Denosumab Biosimilar (AVT03)
Dr. Reddy's Laboratories' Swiss subsidiary has received a Complete Response Letter (CRL) from the USFDA regarding its Biologics License Application (BLA) for AVT03, a biosimilar candidate for Prolia and Xgeva. The CRL is not related to the drug's efficacy but stems from observations during a pre-license inspection of partner Alvotech's manufacturing facility in Reykjavik, Iceland. This regulatory setback delays the potential US market entry for this high-value biosimilar. The company will need to wait for Alvotech to resolve these facility-level observations before seeking re-approval.
முக்கிய அம்சங்கள்
USFDA issued a Complete Response Letter (CRL) for the BLA of AVT03 (denosumab).AVT03 is a biosimilar candidate for blockbuster drugs Prolia and Xgeva.The CRL is linked to inspection observations at Alvotech's Reykjavik manufacturing facility.The product is being developed in partnership with Alvotech hf.Approval delay impacts the timeline for Dr. Reddy's biosimilar portfolio expansion in the US.
👀 கவனிக்க வேண்டியவை
Investors should monitor Alvotech's progress in resolving USFDA facility observations, as the product's approval is contingent on this. While this is a delay rather than a rejection, it may impact medium-term growth expectations for the US biologics segment.
Dr. Reddy's Srikakulam Facility Receives USFDA Form 483 With 5 Observations
The USFDA completed a combined GMP and Pre-Approval Inspection (PAI) at Dr. Reddy's formulations facility (FTO-SEZ PU01) in Srikakulam, Andhra Pradesh. The inspection, which took place from December 4 to December 12, 2025, concluded with the issuance of a Form 483 containing 5 observations. The company has committed to addressing these observations within the stipulated timeline to ensure compliance and mitigate potential delays in product approvals.
முக்கிய அம்சங்கள்
USFDA inspection conducted at the Srikakulam formulations facility (FTO-SEZ PU01) between Dec 4 and Dec 12, 2025.The audit was a dual-purpose Good Manufacturing Practice (GMP) and Pre-Approval Inspection (PAI).A Form 483 was issued by the regulator with 5 specific observations.The company intends to submit a response and address the findings within the required timeframe.
👀 கவனிக்க வேண்டியவை
Investors should monitor the severity of the observations and the USFDA's final classification, as these could impact future product launches from this specific SEZ unit.
Dr. Reddy's Announces Net Zero Climate Target by FY2045
Dr. Reddy's Laboratories commits to achieving Net Zero greenhouse gas emissions across its value chain by FY2045. In the near term, the company aims to reduce absolute Scope 1 and 2 greenhouse gas (GHG) emissions by 80% and Scope 3 emissions by 51.6% per INR value added by FY2030, using FY2023 as the base year. Long term, Dr. Reddy's commits to reducing absolute Scope 1, 2, and 3 emissions by 90% by FY2045, again from the FY2023 baseline. The company is also on track to achieve coal- and furnace oil–free operations by the end of FY’26, with 68% of its power in FY’25 sourced from renewables.
முக்கிய அம்சங்கள்
Commits to Net Zero greenhouse gas emissions by FY2045Reduce Scope 1 and 2 GHG emissions by 80% by FY2030Reduce Scope 3 emissions by 51.6% per INR value added by FY2030Reduce absolute Scope 1, 2, and 3 emissions by 90% by FY204568% of power in FY’25 sourced from renewables
👀 கவனிக்க வேண்டியவை
Investors should monitor Dr. Reddy's progress towards its sustainability goals and assess the impact of these initiatives on the company's long-term financial performance. Keep an eye on the company's transition to renewable energy sources and the reduction of its carbon footprint.
Dr. Reddy's signs $369.5M licensing deal with Immutep for oncology drug Eftilagimod Alfa
Dr. Reddy's Laboratories has entered into a strategic collaboration with Immutep SAS for the exclusive licensing of Eftilagimod Alfa, a first-in-class immunotherapy for cancer. The agreement covers all global markets except North America, Europe, Japan, and Greater China. Dr. Reddy's will pay an upfront fee of USD 20 million and up to USD 349.5 million in potential regulatory and commercial milestones, plus double-digit royalties. The drug is currently in Phase III trials for non-small cell lung cancer, representing a significant addition to Dr. Reddy's innovative oncology pipeline.
முக்கிய அம்சங்கள்
Upfront payment of USD 20 million (~AUD 30.2 million) to be paid to Immutep.Eligible for milestone payments up to USD 349.5 million (~AUD 528.4 million) plus double-digit royalties.Exclusive rights to develop and commercialize in all countries outside North America, Europe, Japan, and Greater China.Target drug Eftilagimod Alfa is in Phase III clinical trials for first-line non-small cell lung cancer.Immutep retains global manufacturing rights and will supply the product to Dr. Reddy's.
👀 கவனிக்க வேண்டியவை
Investors should monitor the progress of the Phase III TACTI-004 trials as successful commercialization could significantly boost Dr. Reddy's branded oncology portfolio in emerging markets. This deal signals a strong shift towards high-value innovative therapies over traditional generics.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
